BURLINGTON, Mass., March 18 /PRNewswire-FirstCall/ --
Palomar Medical Technologies Inc (Nasdaq: PMTI) today announced that on
Friday, March 14, 2003, a member of its Board of Directors exchanged a $1
million promissory note for common stock and a private investment firm
invested $3.4 million, both at a premium to market.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO )
On September 28, 2001, the Company borrowed $1 million and issued a demand
note to Mr. Pappalardo, a Director of the Company. On March 14, 2003, the
Director agreed to exchange the principal balance of the note for 293,255
shares of the Company's common stock, at a price of $3.41 per share with no
registration rights. The price was calculated at 110 percent of the Company's
common stock's trailing ten-day average closing price of $3.10.
Also on March 14, 2003, the Company completed a private placement with
Craig Drill Capital, a private investment firm based in New York City, for the
purchase of one million shares of the Company's common stock, at a price of
$3.41 per share with no registration rights for an aggregate subscription
price of $3.41 million. The price was calculated at 110 percent of the
Company's common stock's trailing ten-day average closing price of $3.10.
Chief Executive Officer Joseph P. Caruso commented, "The combination of
the exchange of the note and private placement at a premium to market adds
$4.4 million to our working capital. This enhanced position enables us to
expand operations and exploit our position in the professional market. We are
also in a strong position to advance our technology to the consumer market
with these additional financial resources. The exchange to equity of the
promissory note and private investment demonstrates that both insiders and
outsiders to the Company support and are interested in the Company's direction
and growth potential."
Caruso continued, "We are looking forward to presenting the Company's
latest products at the American Academy of Dermatology's (AAD) 61st Annual
Meeting, in San Francisco, from March 21 to 26, and will be available to give
investor demonstrations and discuss our full line of products at booth #2801.
We have scheduled a full week of meetings leading up to the AAD with various
institutions and funds to continue to increase the following of the Company
within the investment community."
About Palomar Medical Technologies Inc: Palomar is a leading researcher
and developer of light-based systems for hair removal and other cosmetic
treatments. Recently, Palomar and The Gillette Company (NYSE: G) entered into
an agreement to complete development and commercialize a patented home-use,
light-based hair removal device for women. New and exciting indications are
being tested to further advance the hair removal market and other cosmetic
applications. Palomar pioneered the optical hair removal field, when, in 1996,
it introduced the first high-powered laser hair removal system. Since then,
many of the major advances in light-based hair removal have been based on
Palomar technology. There are now millions of light-based hair removal
procedures performed around the world every year in physician offices,
clinics, spas and salons.
For more information on Palomar and its products, visit Palomar's website
at http://www.palmed.com. To continue receiving the most up-to-date information and
latest news on Palomar as it happens, sign up to receive automatic e-mail
alerts by going to the E-mail Alerts page in the Investor Relations' section
of the website.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, challenges in managing joint ventures and
research with third parties, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether
FDA clearance will be obtained for future products, the results of litigation,
difficulties in collecting royalties, potential infringement of third-party
intellectual property rights, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on Form 10-K
for the year ended December 31, 2001 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these forward-
looking statements, which speak only as of the date hereof. The Company
undertakes no obligation to release publicly the result of any revisions to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
Contacts:
Paul S. Weiner
Chief Financial Officer
781-993-2411
ir@palmed.com
SOURCE Palomar Medical Technologies Inc
 back to top
Related links:
http://www.palmed.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/107555.html
CONTACT:
Paul S. Weiner, Chief Financial Officer for
Palomar Medical Technologies Inc, +1-781-993-2411
|
